Pharma Stock Goes 1:10 Stock Split, Faces Selling Heat As Record Date Nears; Time To Exit?

Shukra Pharmaceuticals' stock began Tuesday at Rs 245.70 per share on the BSE, down from the previous closing of Rs 250.70. With a market value of Rs 1.08KCr, the stock saw strong selling pressure during afternoon trading, setting the scrip in a 2% lower circuit limit at Rs 245.70 a share. Following the company's 1:10 split, which has a record date of March 21, 2025, a downward trend was observed in the pharma stock.

Shukra Pharma Notifies New ISIN For Sub-Divided Shares Effective March 21

"This is in continuation to our communication dated March 7 ,2025 with respect to Sub- Division of Equity Shares from the Face Value of Rs. 10 each to Face Value of Rs.1 each fully paid up with effect from Record Date i.e. March 21,2025. Please be informed that the Sub-Division of Equity Shares will take effect under the new ISIN i.e. INE551C01044," said Shukra Pharmaceuticals in a stock exchange filing on Monday.

As per Shukra Pharmaceuticals, the rationale behind the 1:10 stock split is to enhance the liquidity in the capital market, widen the shareholder base and make the shares affordable/ accessible to small/ retail in the stock market.

Shukra Pharma Record Date For 1:10 Stock Split

The record date for determining the eligibility of shareholders for the purpose of splitting or subdividing the company's equity shares is set for Friday, March 21, 2025. This will allow each equity share with a nominal or face value of Rs. 10 to be divided into 10 equity shares with nominal or face values of Rs. 1 each.

Shukra Pharma Q3 Financials

In comparison to the same quarter in the prior fiscal year, Shukra Pharmaceuticals Ltd. reported a significant year-on-year (YoY) degrowth in its financial performance for the quarter ending December 2024 (Q3FY25). The company's net sales decreased by over 44% year on year to Rs 10.58 million in Q3FY25 from Rs 18.89 million in Q3FY24.Net income plunged about 40.4% YoY to Rs 11.59 million in Q3FY25 from Rs 19.45 million in Q3FY24. Profit Before Tax (PBT) dropped around 57% YoY, from Rs 9.53 million in Q3FY24 to Rs 4.10 million in Q3FY25. In Q3FY25, net profit dropped to Rs 3.16 million from Rs 9.42 million in Q3FY24, representing a steep YoY decline of around 66.5%.

Shukra Pharma Share Price Target

"Shukra Pharmaceuticals stock price is bearish on the Daily charts with strong resistance at 271. A Daily close below support of 227 could lead to a target of 191 in the near term," commented A R Ramachandran, Independent Research Analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.